

Please type a plus sign (+) inside this box →

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number



Substitute for form 1449APTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 4

Complete if Known

RECEIVED

AUG 05 2002

TECH CENTER 1600/2900  
EV 032 196 842 US

U.S. PATENT DOCUMENTS				
		U.S. Patent Document		
Examiner Initials*	Cite No. <sup>1</sup>	Number	Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document
<i>AMO</i>	1	4,166,452		Generales, Jr.
	2	4,265,874		Bonsen, et al.
	3	4,356,108		Schwab, et al.
	4	4,873,313		Crawford, et al.
	5	5,202,424		Vlassara, et al.
	6	5,585,344		Vlassara, et al.
	7	5,688,653		Ulrich, et al.
	8	5,864,018		Morser, et al.
	9	5,939,526		Gaugler, et al.
	10	6,100,098		Newkirk
				Date of Publication Cited Document MM-DD-YYYY
				Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS				
		Foreign Patent Document		
Examiner Initials*	Cite No. <sup>1</sup>	Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>2</sup> (if known)
<i>AMO</i>	11	WO	00/20458	The Trustees of Columbia University in NYC
	12	WO	00/20621	The Trustees of Columbia University in NYC
	13	WO	97/26913	The Trustees of Columbia University in NYC
	14	WO	97/39121	Schering Aktiengesellschaft
	15	WO	9739125	Schering Aktiengesellschaft
	16	WO	98/22138	The Trustees of Columbia University in NYC
	17	WO	99/07402	The Trustees of Columbia University in NYC
	18	WO	99/18987	The Trustees of Columbia University in NYC
	19	WO	99/54485	The Trustees of Columbia University in NYC
	20	WO	95/09838	Merrell Dow Pharmaceuticals Inc.
	21	WO	95/35279	Merrell Pharmaceuticals Inc.
	22	WO	97/22618	Vertex Pharmaceuticals Incorporated
	23	WO	96/32385	Hoechst Marion Roussel Inc.
	24	WO	99/50230	Vertex Pharmaceuticals Incorporated
				Date of Publication Cited Document MM-DD-YYYY
				Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
				T <sup>6</sup>

1.. 8/1

March 2004

Please type a plus sign (+) inside this box

PTO/SB/08A (08-00)

Approved for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449APTO

JUL 30 2002

Complete if Known

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

2

of

4

Application Number

10/091,759

Filing Date

March 5, 2002

First Named Inventor

Adnan M.M. Mjalli

Group Art Unit

1614

Examiner Name

Unassigned

Attorney Docket Number

41305-271123 (2001-24)

Express Mail Certificate

EV 032 196 842 US

RECEIVED

AUG 05 2002

USPTO CENTER

600/2900

110	25	GB	2 005 674		Carlo Erba S.p.A.	04-25-79		✓
↑	26	WO	98/33492		Fox Chase Cancer Center	08-06-98		✓
↓	27	WO	99/25690		University of Kansas Medical Center	05-27-99		✓
110	28	WO	01/12598		The Trustees of Columbia University in New York City, NY	02-22-01		✓

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
110	29	Albercio, F. & Carpinio, L.A., "Coupling Reagents and Activation" <i>Methods in Enzymology</i> 289:104-126, Academic Press, San Diego (1997)	✓
↑	30	Barton, J.W., "In Protection of N-H Bonds and NR <sub>3</sub> " <i>Protective Groups in Organic Chemistry</i> , J.F.W. McOmie, ED., Plenum Press, New York, NY (1973)	✓
	31	Berge, S.M., et al., "Pharmaceutical Salts" <i>Journal of Pharmaceutical Sciences</i> 66:1-19 (1977)	✓
	32	Chitaley, K., et al., "Antagonism of Rho-Kinase Stimulates Rate Penile Erection via a Nitric Oxide-Independent Pathway" <i>Nature Medicine</i> 7:119-122 (2002)	✓
	33	Degenhardt, T.P., et al., "Chemical Modification of Proteins by Methylglyoxal" <i>Cell Mol. Biol.</i> , 44:1139-1145 (1998)	✓
	34	Dyer, D.G., et al., "Accumulation of Maillard Reaction Products in Skin Collagen in Diabetes and Aging" <i>J. Clin. Invest.</i> , 91:2463-2469 (1993)	✓
	35	Dyer, D.G., et al., "Formation of Pentosidine during Nonenzymatic Browning of Proteins by Glucose" <i>J. Biol. Chem.</i> , 266:11654-11660 (1991)	✓
	36	Greene, T.W., "Protection for the Amino Group" <i>Protective Groups in Organic Synthesis</i> , John Wiley and Sons, New York, NY, Chapter 7 (1981)	✓
	37	Hammes, H.P., et al., "Diabetic Retinopathy Risk Correlates with Intracellular Concentrations of the Glycoxidation Product N <sup>ε</sup> -(Carboxymethyl) Lysine Independently of Glycohaemoglobin Concentrations" <i>Diabetologia</i> , 42:603-607 (1999)	✓
	38	Hoffman, M.A., et al., "RAGE Mediates a Novel Proinflammatory Axis: A Central Cell Surface Receptor for S100/Calgranulin Polypeptides" <i>Cell</i> , 97:889-901 (1999)	✓
↓	39	Hori, O., et al., "The Receptor for Advanced Glycation End Products (RAGE) Is a Cellular Binding site for Amphotericin" <i>J. Biol. Chem.</i> , 270:25752-761 (1995)	✓
110	40	Huttunen, H.J., et al., "Receptor for Advanced Glycation End Products (RAGE)-Mediated Neurite Outgrowth and Activation of NF-Kappa B Require the Cytoplasmic Domain of the Receptor But Different Downstream Signaling Pathways" <i>J. Biol. Chem.</i> 274(28):19919-24 (1999)	✓

110.21 March 2002

Please type a plus sign (+) inside this box

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number



JUL 3 2002

Complete if Known

RECEIVED

Substitute for form 1449APTO

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 4

Application Number

10/091,759

Filing Date

March 5, 2002

First Named Inventor

Adnan M.M. Mjalli

Group Art Unit

1614

Examiner Name

Unassigned

Attorney Docket Number

41305-271123 (2001-TECH CENTER 1600/2900)

AUG 05 2002

Express Mail Certificate

EV 032 195 842 US

100	41	Kumar, S.R., et al., "RAGE at the Blood-Brain Barrier Mediates Neurovascular Dysfunction Caused by Amyloid $\beta$ <sub>1-40</sub> Peptide" <i>Neurosci. Program.</i> , 141:#255.19 (2000)	✓
↑	42	Leder, A. et al., "v-HA-ras Transgene Abrogates the Initiation Step in Mouse Skin Tumorigenesis: Effects of Phorbol Esters and Retinoic Acid" <i>Proc. Natl. Acad. Sci., USA</i> , 87:9178-9182 (1990)	✓
	43	Li, J. et al., "Sp1-Binding elements in the Promoter of RAG Are Essential for Amphotericin-Mediated Gene Expression in Cultured Neuroblastoma Cells." <i>J. Biol. Chem.</i> , 273:30870-30878 (1998)	✓
	44	Li, J. et al., "Characterization and Functional Analysis of the Promoter of RAGE, the Receptor for Advanced Glycation End Products," <i>J. Biol. Chem.</i> , 272:16498-16506 (1997)	✓
	45	Lugering, N. et al., "The Myeloid Related Protein MRP8/14 (27E10 Antigen)—Usefulness as a Potential Marker for Disease Activity in Ulcerative Colitis and Putative Biological Function" <i>Eur. J. Clin. Invest.</i> , 25:659-664 (1995)	✓
	46	Miyata, T. et al., " $\beta_2$ -Microglobulin Modified with Advanced Glycation End Products Is a Major Component of Hemodialysis-Associated Amyloidosis" <i>J. Clin. Invest.</i> , 92:1243-1252 (1993)	✓
	47	Miyata, T. et al., "The Receptor for Advanced Glycation End Products (RAGE) Is a Central Mediator of the Interaction of AGE- $\beta_2$ Microglobulin with Human Mononuclear Phagocytes Via an Oxidant-Sensitive Pathway" <i>J. Clin. Invest.</i> , 98:1088-1094 (1996)	✓
	48	Nepper, M. et al., "Cloning and Expression of a Cell Surface Receptor for Advanced Glycosylation End Products of Proteins" <i>J. Biol. Chem.</i> , 267:14998-15004 (1992)	✓
	49	Parkkinen, J. et al., "Amphoterin, the 30-kDa Protein in a Family of HMG1-Type Polypeptides" <i>J. Biol. Chem.</i> , 268:19726-19738 (1993)	✓
	50	Ramases, A. et al., "Myeloid-Related Protein (MRP) 8 and MRP 14, Calcium-Binding Proteins of the S100 Family, Are Secreted by Activated Monocytes via a Novel, Tubulin-Dependent Pathway" <i>J. Biol. Chem.</i> , 272:9496-9502 (1997)	✓
	51	Rauvala, H. et al., "Isolation and Some Characteristics of an Adhesive Factor of Brain That Enhances Neurite Outgrowth in Central Neurons" <i>J. Biol. Chem.</i> , 262:16625-16635 (1987)	✓
↓	52	Reddy, S. et al., "N <sup>ε</sup> -(Carboxymethyl) Lysine Is a Dominant Advanced Glycation End Product (AGE) Antigen in Tissue Proteins" <i>Biochem.</i> , 34:10872-10878 (1995)	✓
	53	Schafer, B.W., et al., "The S100 Family of EF-Hand Calcium-Binding Proteins: Functions and Pathology" <i>TIBS</i> , 21:134-140 (1996)	✓
	54	Schleicher, E.D., et al., "Increased Accumulation of the Glycoxidation Product N <sup>ε</sup> -(Carboxymethyl) Lysine in Human Tissues in Diabetes and Aging" <i>J. Clin. Invest.</i> , 99(3):457-468 (1997)	✓
100	55	Schmidt, A.M. et al., "The Dark Side of Glucose" <i>Nature Med.</i> , 1:1002-1004 (1995)	✓

✓ P.M. March 2002

Please type a plus sign (+) inside this box

PTO/SB/08A (08-00)

Approved for use through 10/31/2002 OMB 0651-0031  
U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person

is required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449APTO

JUL 3 0 2002

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

4 of 4

Complete if Known

Application Number	10/091,759
Filing Date	March 5, 2002
First Named Inventor	Adnan M.M. Mjalli
Group Art Unit	1614
Examiner Name	Unassigned
Attorney Docket Number	41305-271123 (2001-21)

RECEIVED

AUG 05 2002

TECH CENTER 1600/2900

Express Mail Certificate

EV 032 196 842 US

140	56	Schmidt, A.M., et al., "The V-Domain of Receptor for Advanced Glycation Endproducts (RAGE) Mediates Binding of AGEs: A Novel Target for Therapy of Diabetic Complications." <i>Supplement to Circulation</i> Vol. 96, #194 (1997)	✓
1	57	Taguchi, A. et al., "Blockade of RAGE—Amphoterin Signalling Suppresses Tumour Growth and Metastases" <i>Nature</i> , 405:354-360 (2000)	✓
	58	Tanaka, N., et al., "The Receptor for Advanced Glycation End Products Is Induced by the Glycation Products Themselves and Tumor Necrosis Factor- $\alpha$ through Nuclear Factor- $\kappa$ B, and by 17 $\beta$ -Estradiol through Sp-1 in Human Vascular Endothelial Cells" <i>J. Biol. Chem.</i> , 275:25781-25790 (2000)	✓
	59	Teillet et al., "Food Restriction Prevents Advanced Glycation End Product Accumulation and Retards Kidney Aging in Lean Rats" <i>J. Am. Soc. Nephrol.</i> , 11:1488-1497 (2000)	✓
	60	Vlassara, H., "Advanced Glycation End-Products and Atherosclerosis" <i>The Finnish Medical Society DUODECIM, Ann. Med.</i> , 28:419-426 (1996)	✓
	61	Wautier et al., "Receptor-Mediated Endothelial Cell Dysfunction in Diabetic Vasculopathy: Soluble Receptor for Advanced Glycation End Products Blocks Hyperpermeability in Diabetic Rats" <i>J. Clin. Invest.</i> , 97:238-243 (1996)	✓
	62	Yan, S.-D., et al., "RAGE and Amyloid- $\beta$ Peptide Neurotoxicity in Alzheimer's Disease" <i>Nature</i> 382:685-691 (1996)	✓
	63	Yan, S.-D., et al., "An Intracellular Protein That Binds Amyloid- $\beta$ Peptide and Mediates Neurotoxicity in Alzheimer's Disease" <i>Nature</i> , 389:689-695, (1997)	✓
	64	Yan, S.-D. et al., "Amyloid- $\beta$ Peptide—Receptor for Advanced Glycation Endproduct Interaction Elicits Neuronal Expression of Macrophage-Colony Stimulating Factor: A Proinflammatory Pathway in Alzheimer Disease" <i>Proc. Natl. Acad. Sci., USA</i> , 94:5296-5301 (1997)	✓
	65	Yan, S.-D. et al., "Receptor-Dependent Cell Stress and Amyloid Accumulation in Systemic Amyloidosis" <i>Nat. Med.</i> 6:643-651 (2000)	✓
	66	Yan, S.-D. et al., "Enhanced Cellular Oxidant Stress by the Interaction of Advanced Glycation Endproducts With Their Receptors Binding Proteins" <i>J. Biol. Chem.</i> 269:9889-9897 (1994)	✓
143	67	Zimmer, D. et al., The S100 Protein Family: History, Function, and Expression" <i>Brain Res. Bull.</i> , 37:417-429 (1995)	✓
143	68	International Search Report for PCT/US 01/17251 dated 8/14/01	✓

Examiner  
Signature

Date  
Considered

March 2004

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformation and not considered.  
Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

41305-271123

WINLIB01:956774.1